Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as PF-06882961 Immediate Release Tablet
PF-06882961 Immediate Release · 1 trial · 1 indication
AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC (0-t) plus AUC (t-inf).
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood (rate at which a drug is metabolized or eliminated by normal biological processes). Calculated as Dose/AUCinf
Calculated as ratio of Cmax to C24
| Arm | Type | Description |
|---|---|---|
| PF-06882961 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PF-06882961 Immediate Release Tablet | DRUG | Immediate Release Tablet |
| PF-06882961 Controlled Release Tablet (long) | DRUG | Controlled Release tablet (long) |
| PF-06882961 Controlled Release Tablet (short) | DRUG | Controlled Release tablet (short) |
| PF-06882961 Immediate Release Solution | DRUG | PF-06882961 Immediate Release solution |
Inclusion Criteria: * Healthy female subjects of nonchildbearing potential and/or male subjects who, at the time of screening, are between the ages of 18 and 55 years, inclusive * Body mass index (BMI) within 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lb) * Evidence of a personally si...
PF-06882961 Immediate Release is an investigational small molecule developed by Pfizer, Inc. (ticker PFE). It is also known as PF-06882961 Immediate Release Tablet. The formulation has been studied in a Phase 1 clinical trial in healthy adult subjects, and no approved indication has been disclosed for it.
PF-06882961 Immediate Release is made and developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer sponsored the Phase 1 formulation study of the immediate release tablet in healthy subjects.
PF-06882961 Immediate Release is in Phase 1 development. It is investigational and has not been approved by the FDA. One Phase 1 trial has been completed, and no active trials of this immediate release formulation are currently listed.
PF-06882961 Immediate Release has been evaluated in one completed Phase 1 trial, NCT03492697. Titled a single dose crossover study in healthy subjects to evaluate different formulations of PF-06882961, it enrolled 12 healthy adult volunteers in the United States. The study was randomized but uncontrolled and not double blind.
Yes. PF-06882961 Immediate Release Tablet is another name for PF-06882961 Immediate Release, the Pfizer small molecule formulation studied in the Phase 1 trial NCT03492697. Both names refer to the same immediate release oral product.